Funding for this research was provided by:
Ministry of Health and Welfare (HQ20C0076)
Received: 29 September 2022
Accepted: 14 November 2022
First Online: 30 November 2022
: This study was approved in South Korea by the Korea Ministry of Food and Drug Safety (approval #33475) and Institutional Review Board at 5 sites; Catholic University of Korea, Eunpyeong St. Mary’s Hospital (approval #PC21BDDF0015), Soonchunhyang University Bucheon Hospital (approval #SCHBC 2021–03-017), Hanyang University College of Medicine (approval #GURI 2021–03-044), Catholic University of Korea, Bucheon St. Mary’s Hospital (approval #HC21BDDS0027), and Ewha Womans University Seoul Hospital (approval #SEUMC 2021–03-038). The study was registered with ClinicalTrials.gov (NCT04783311).
: Written informed consent was obtained from all participants.
: J.F.L. holds interest in POP Biotechnologies. W.-C. H. holds interest in and is an employee of POP Biotechnologies. Y.O. B., S. K. C., C. L., hold interest in and are employees of Eubiologics. J. Y. L. is an employee of Eubiologics.